Caffeine

1. INCI & CAS

INCI: Caffeine · CAS: 58-08-2

2. Role in the formula

Caffeine is used around 0.2–1% in cosmetic eye gels. This page does not claim a medical eye treatment.

3. Typical use levels (formulation guide)

• The level shown for eye gels and serums is 0.2–1% as a formulation guide.

Dissolve into water.

4. Regulatory sources & global compliance

• A CosIng entry naming Caffeine does not by itself approve the purchased grade or complete cosmetic.
• For an EU-market product, Regulation (EC) No 1223/2009 requires a safety assessment covering the complete formulation with Caffeine before the finished product is marketed.
• Match the selected Caffeine material to its supplier TDS and check the filing list for the market of sale.

5. Safety & risk assessment

The listed use rate is intended as a cosmetic-development guide; it should not be read as a drug authorization or OTC listing so assess patch response and stability in the final formula.

6. Stability & packaging

Hold the bulk material in a sealed, cool place shielded from light; for oxidation-sensitive formulas, consider an airless or pump pack; follow with stability and packaging checks on the confirmed batch.

7. Claims language (Do / Don’t)

• The cosmetic concept for Caffeine in this entry centers on caffeine eye-care.

• The ingredient record does not substantiate claims of drug action or cure, or a product certification outside the supporting records.
• This guide to Caffeine should not be cited in support of whitening, acne care as treatment, perspiration reduction, sun protection, or hair growth.

1. INCI & CAS

INCI: Glycerin · CAS: 56-81-5

2. Role in the formula

For emulsions, gels, and washes, this guide assigns glycerin a polyol-humectant role. Its level is not a batch assay.

3. Typical use levels (formulation guide)

• Gels and serums: 3–8% for the formula.
• The creams use-level reference is 2–5% for the formula.
• The level shown for rinse-off is 2–4% for the formula.

Add Glycerin to the water phase; no separate melt step is needed.

4. Regulatory sources & global compliance

• CosIng provides reference information for Glycerin; confirm the specific grade and intended use against market requirements.
• An EU-market cosmetic under Regulation (EC) No 1223/2009 requires a safety assessment covering the complete formulation with Glycerin for the product in its final form.
• Use the supplier TDS to confirm grade-specific details for Glycerin and review the destination market's requirements.

5. Safety & risk assessment

The listed use rate is intended as a cosmetic-development guide; it does not establish drug approval or OTC-monograph status so the finished cosmetic should receive patch and stability checks.

6. Stability & packaging

Store sealed bulk away from heat and sunlight; if the formula is oxidation-sensitive, an airless or pump format may be considered; follow with stability and packaging checks on the confirmed batch.

7. Claims language (Do / Don’t)

• For cosmetic use, this entry records Glycerin in a direction centered on humectant function.

• The listed information cannot verify drug or therapeutic claims, clinical cures, or certification claims not confirmed for the product.
• This Glycerin listing does not confirm whitening, acne treatment, antiperspirant effects, sunscreen use, or hair growth.

1. INCI & CAS

INCI: Squalane · CAS: 111-01-3

2. Role in the formula

The guide uses plant-derived squalane, a stable hydrocarbon emollient, and does not specify mineral oil.

3. Typical use levels (formulation guide)

• For gel-creams, the reference gives 2–6% as a formulation guide.
• Formulation guidance for dry oils: 10–30% in this reference.
• For balms, the recorded level is 5–15% as a formulation guide.

Use the oil phase to introduce Squalane; a high-shear wax stage is not specified.

4. Regulatory sources & global compliance

• If CosIng lists Squalane, that listing remains ingredient information; check rules for the intended market and use.
• For cosmetics placed on the EU market, Regulation (EC) No 1223/2009 requires an assessment of the safety of the final cosmetic containing Squalane before the finished product is marketed.
• Review the supplier TDS for the received Squalane grade, together with the target market's current filing requirements.

5. Safety & risk assessment

The concentration shown is guidance for cosmetic formulation; it does not establish drug approval or OTC-monograph status so patch response and stability should be checked on the finished product.

6. Stability & packaging

Keep the bulk container closed and shaded in a cool area; review airless or pump options if oxidation presents a concern; confirm final stability and pack compatibility on a representative batch.

7. Claims language (Do / Don’t)

• This guide frames Squalane's cosmetic direction around a light-emollient role.

• The ingredient record cannot substantiate drug claims, cure claims, or a certification that is absent from the product records.
• This guide to Squalane is not evidence for whitening, acne care as treatment, perspiration reduction, sun protection, or hair growth.